Ann: OLE Study update reveals impressive Survival Data, page-217

the longer we don’t here anymore news the better. OLE next readout is when 50% of patients unfortunately pass away. On the radar will be preclinical neurodegenerative. Whilst we could go sub 16c this is placing basically next to no chance of success, obviously market simply ignoring P1 results and / or not willing to way until 2026. Gives me some breathing space to accumulate whilst I can.

my gut says says all pointing in the right direction and we are a 5x to the spark valuation upon entry to Healy. Risk is sporadic nature of MND making it difficult to translate to statistically significance in the clinic. Data matched controls in Protact database and P1 suggests either we were just super lucky in P1 (eg it was a fluke) or this thing is the real deal.

what I have learnt is repurposed drugs have lower risks going into P2/P3 that the market doesn’t seem to pay much attention too. It using the rule of averages and applies this broadly in biotech thus an opportunity for me.

Also P1 can be just safety data, in most instances but not always the case. In diseases such as MND survival and ALSFRS-R decline can correlate to NFL biomarker isn’t just a coincidence, nor was the outcomes once low to high dose.

Market will likely sit on the sidelines until Healy readouts but will instos and Pharma, I hope so.

DYOR